Chair's Address and CEO Presentation
Released
Released
Announcement PDF
ASX Announcement
30 May 2022
Chair’s Address & CEO Presentation
Melbourne, Australia, 30 May 2022: Avecho Biotechnology Limited (ASX:AVE, “Avecho”, or “the Company”)
attaches the Chair’s Address and the Chief Executive Officer’s Presentation for the Annual General Meeting of
30 May 2022.
- ENDS This announcement is authorised for release by the Board of Directors of Avecho Biotechnology Limited.
Investor + General Enquiries
Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products
using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from
Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral,
dermal and transdermal absorption of drugs and nutrients.
Avecho's major projects include delivering TPM ® enhanced injectable, oral and topical products for the human
health market and is also developing TPM® to enhance the feed efficiency and health of livestock.
See more here - avecho.com.au
Forward-Looking Statements
Certain statements in the Chair’s Address and the Chief Executive Officer’s Presentation are forward looking
statements. Forward looking statements can generally be identified by the use of words such as “anticipate”,
“estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar
import. These forward-looking statements speak only as at the date of this announcement. These statements
are based on current expectations and beliefs and, by their nature, are subject to a number of known and
unknown risks and uncertainties that could cause the actual results, performances and achievements to differ
materially from any expected future results, performance or achievements expressed or implied by such
forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by Avecho that the forwardlooking statements contained in these materials are accurate, complete, reliable or adequate or that they will
be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Avecho and its
respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or
completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for
any direct or indirect loss or damage which may be suffered by any person as a consequence of any information
in these materials or any error or omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho disclaims
any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in
these materials to reflect any change in expectations in relation to any forward looking statements or any
change in events, conditions or circumstances on which any statemnent is based. Nothing in these materials
shall under any circumstances create an implication that there has been no change in the affairs of Avecho
since the date of the announcement.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Chair’s Address
Dear Shareholders,
I am pleased to share a Company update on behalf of Avecho Biotechnology Limited to coincide with Company’s
Annual General Meeting (AGM) today.
The last year has been defined by significant progress for our cannabinoid (CBD) programs. Our oral CBD
capsule completed its Phase I clinical trial; our topical CBD gel showed promise in a Phase II osteoarthritis trial;
and we executed our first licensing and partnership agreements in the cannabis space for both short and longterm gain.
Right now, our focus remains on developing our oral CBD capsule, including immediate pivotal clinical and
regulatory work in order to support a regulatory submission to the TGA. Alongside this, our topical formulation
is on track to address novel applications for conditions like osteoarthritis.
Our Company is primed for growth, and we already have strong interest in the CBD product from further
potential licensees. We are moving forward, methodically and with great care, to deliver value for our investors.
Key Achievements
> CBD Capsule: Clear Path to Registration
This year we have focused on the continued advancement of our CBD TPM® capsule. In December last year,
we announced the completion of our Phase I Clinical trial that characterised the absorption profile of CBD from
our proprietary capsule. This was a key milestone that now enables progress into our planned Phase III
clinical trial and will also form a pivotal piece of our data package to support the registration of our softgel product with the TGA.
> First Licensing Deal for the CBD TPM capsule
The completion of our Phase I study triggered an immediate licensing deal for the CBD TPM® capsule in the
US. Perland Pharma (previously named Medterra Pharma) licensed the product for use in arthritis indications.
Perland will fund all clinical development in the indication, with studies scheduled to begin this year. This
partnership will place the CBD capsule before the FDA and provides Avecho with potential pathway for another
indication that we did not intend to immediately pursue ourselves. This is a model we intend to explore further,
and we are in ongoing discussions with several additional potential licensees.
> Recreational Cannabis: Immediate Revenue
The work we have done on the pharmaceutical development of cannabinoids, has generated interest and a
subsequent first deal for the use of TPM® in the broader cannabis market. We recently entered into a licensing
and supply agreement with US-based company, Team SAAS LLC, to use our TPM® technology to develop and
commercialise a unique cannabis distillate for use in consumer cannabis products in the US. Recreational
cannabis represents a large and lucrative market, with sales of cannabis-related products totalling
US$17.5B in 2020. With little in the way of product differentiation, it is hoped that TPM® sales into the space
could be significant and provide a valuable source of future revenue to support Avecho’s ongoing research and
development (R&D).
> Focused Research for New Indications
In addition to commercial partnerships, Avecho has also established important research collaborations as it
explores new cannabinoid dosage forms. In collaboration with the Lambert Initiative, Avecho completed a
successful Phase II clinical trial that examined whether CBD could provide relief from symptoms of
osteoarthritis. The results of this early study were very positive and justify further clinical development of
topical cannabinoid gels using TPM®.
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Avecho’s work on cannabinoids continues to build value for the Company and these programs will remain the
focus for our investment moving forward. We hope that the next year will see even further advancements.
Financial Outlook
Avecho has a secure balance sheet with sufficient resources to progress all the work and near-term milestones.
This will be further supported by our manufacturing program and commercial partnerships, which are principally
focused on sustainable revenue generation. Our Company also remains committed to using cash resources to
invest in research and development, and licensing activities.
Conclusion
On behalf of the Avecho team I would like to express our gratitude for your continued support. We are on track
to drive promising commercial activity in the CBD space in the year ahead – having delineated clear goal posts
with key regulators and backing from reputable commercial partners.
Thank you for your continued support and we look forward to keeping you updated with our progress.
Dr Greg Collier
Avecho Biotechnology Limited Chairman
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
ANNUAL GENERAL MEETING
30TH MAY 2022
www.avecho.com.au
| ASX:AVE
SAFE HARBOUR STATEMENT
AVECHO BIOTECHNOLOGY
This presentation, and any representations made before, during or after the presentation, may include forwardlooking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not
limited to: (1) the safety or efficacy of, or potential applications for, Avecho’s TPM® platform technology; (2) the
strength of Avecho‘s intellectual property; (3) the timelines for Avecho’s clinical trials and regulatory processes for its
different products; (4) the scalability and efficiency of manufacturing processes; (5) revenue projections, market
share expectations, share price expectations and capital requirements.
Actual results may differ from the expectations expressed in these forward-looking statements, and the differences
may be material (whether positive or negative). The risks that may cause Avecho‘s actual results, performance or
achievements to be materially different from those expressed or implied by such forward-looking statements, include
but are not limited to: (1) risks inherent in the development, approval and commercialization of potential products;
(2) uncertainty of clinical trial results or regulatory approvals or clearances; (3) changes to market trends or
government laws or regulations; (4) the potential need for future capital; (5) dependence upon collaborators; and
(6) protection of intellectual property rights, among others. Accordingly, you should not place undue reliance on
these forward-looking statements.
May 2022
AVECHO BIOTECHNOLOGY I May 2022
2
2
FAST FACTS
•
Building proprietary differentiated cannabinoid products with TPM® delivery technology
•
First 75 mg CBD capsule completed with Catalent, USA (May 2021)
•
Phase I PK study completed (Dec 2021) – characterised absorption
•
Australian Phase III trial for an insomnia indication to start 2022
•
Targeting over-the-counter registration in Australia, followed by ROW
•
Licenses signed for CBD capsule and TPM in overseas markets (Dec 21-Feb 22).
•
Revenue generating manufacturing business to support R&D
May 2022
AVECHO BIOTECHNOLOGY I May 2022
3
3
CLEAR STRATEGIC FOCUS
1. Develop, TGA register and commercialise a
proprietary pharmaceutical CBD capsule
containing TPM
2. License this and other TPM cannabinoid
dosage forms in multiple indications,
territories and markets
May 2022
AVECHO BIOTECHNOLOGY I May 2022
4
4
LEGACY PROGRAMS
HUMAN HEALTH
ANIMAL HEALTH
•
•
Multiple potential licensees undertaking due
AB Vista will not continue with TPM®
•
diligence.
•
•
development.
•
Multiple assets being considered
than internal product under development.
•
May 2022
Study showed feeds containing TPM improve
diarrhea in pigs, but not significantly better
Minimal investment moving forward
AVECHO BIOTECHNOLOGY I May 2022
AB Vista has its own internal product under
Still waiting EFSA decision
5
5
PHARMACEUTICAL
CBD CAPSULE
CANNABINOIDS AS MEDICINE
Medicinal cannabis extracts are being legalized around the world
Some markets are also allowing consumer and recreational uses
Unregistered medicinal cannabis products are being prescribed for a range of
therapeutic indications.
Normal R&D into formulation development has been minimal, and the initial
product offerings were simple oil based formulations.
A range of more acceptable dosage forms are required to fulfil the needs of
patients, physicians and consumers.
AVECHO BIOTECHNOLOGY I May 2022
7
THE PROBLEM WITH CANNABINOIDS
Cannabinoids are oil soluble molecules with low solubility in water
Oil soluble molecules have poor oral bioavailability, which is also true for
cannabinoids (3-8% absorbed)
This presents challenges for developing formulations that can deliver cannabinoids
to the body efficiently.
Increasing cannabinoid bioavailability has become a focus for many laboratories
around the world, as increasing bioavailability can allow;
✓ Greater therapeutic effect
✓ New indications, previously untreatable because of high doses required
✓ Reduced dosing for cost savings to patients
✓ Provide commercial differentiation
May 2022
AVECHO BIOTECHNOLOGY I May 2022
8
8
AVECHO’S TPM® INCREASES CANNABINOID ABSORPTION
CBD Solubility
Increased oral absorption
Increased topical absorption
Increased CBD Solubility…
With TPM
May 2022
Without TPM
AVECHO BIOTECHNOLOGY I May 2022
9
9
PHARMACEUTICAL CBD TPM CAPSULE COMPLETE
•
Formulations developed over the last 2 years; increase CBD
absorption in animal models
•
Capsule finalised at Catalent, USA (May 21)
•
75 mg of ultra-pure, synthetic CBD (Purisys) per capsule
•
Product shows good stability (ongoing).
•
Phase I pharmacokinetic (PK) study to characterise the CBD
absorption completed (Dec 21)
•
Phase III clinical trial to be conducted in Australia in a sleep
related indication.
•
Product seeking TGA approval as an over-the-counter (S3)
medicine.
•
International PCT patent applications filed to protect formulation
May 2022
AVECHO BIOTECHNOLOGY I May 2022
10
10
PHASE I TRIAL: CHARACTERISING CBD
ABSORPTION
•
Demonstrated single dose pharmacokinetic (PK) profiles
of 75 mg and 150 mg oral CBD capsule - Primary
objective
•
Demonstrated safety and tolerability, in addition to
absorption of TPM - Secondary objectives
•
Study results will be a vital part of a TGA submission
dossier and future product label
•
Study results will form an important part of BD and
licensing discussions
May 2022
AVECHO BIOTECHNOLOGY I May 2022
First Dose
Second Dose
75 mg
75 mg
150 mg
150 mg
11
11
CBD FOR THE TREATMENT OF INSOMNIA
Insomnia can be broadly defined as difficulty initiating or
maintaining sleep.
40% of Australians getting less sleep than they need
Growing body of prescribing information suggesting that CBD
may alleviate the symptoms of insomnia.
The TGA has confirmed CBD could be registered as an over-thecounter medicine for the treatment of insomnia.
59.4% Experience symptoms 3-4 times per week
Only 20% report their sleep is uninterrupted
~$250M p.a. spent on existing medications with
unwanted side effects
Costs Australian economy $19.1 B per annum
May 2022
AVECHO BIOTECHNOLOGY I May 2022
12
12
DEVELOPMENT PROGRAM (2022-23)
Chemistry, Manufacturing and Control (CMC)
•
Further CMOs engaged for access to other markets (complete)
•
Manufacturing scale up to registration batch (1/10th commercial scale) size (ongoing)
•
Registration batches to be submitted for formal stability (Q3/Q4 2022)
•
Complete CMC dossier for use in registration dossier (2023)
Phase III sleep indication
•
Study design being finalised
•
Service providers being actively identified and engaged
•
Ethics approval expected (Q3 2022)
•
Scaled-up clinical supply available for dosing (Q3/Q4 2022)
Finalised trial
design and
timing will be
the subject of a
future
communication
in the coming
months
Regulatory Submission – Compile and submit dossier to TGA (2023)
Commercialization – Partner to commercialise product in ANZ; Avecho to license product ROW
May 2022
AVECHO BIOTECHNOLOGY I May 2022
13
13
MAXIMISING VALUE FROM THE CBD PRODUCT
DEVELOPMENT
REMAINING DEVELOPMENT
CBD capsule
Phase III
(insomnia)
Further Licenses,
• By Indication
• By Territory
• By Market
May 2022
AVECHO BIOTECHNOLOGY I May 2022
TGA
registration
for insomnia
Avecho licenses
sleep product for
ROW
Commercialise
d by Partner
(ANZ)
Global medical
cannabis market
~$7.8 Bn in 2020;
expected to be
$30-50 Bn by 2027
Global cannabis
market ~20 Bn
(USD) in 2021;
expected to be 90
Bn (USD) by 2026
14
14
CANNABINOID DEALS ALREADY SIGNED
CBD capsule for arthritis
•
CBD capsule licensed (Dec 2021) for arthritis indication (osteo and
rheumatoid arthritis), to Perland (Medterra Pharma)
•
Medterra are one of the most successful consumer CBD companies in the
United States
•
Perland will pay for all development; clinical trials to begin 2022
TPM for the US Recreational Cannabis Space
•
TPM Licensed (Feb 2022) for specific use in the US recreational cannabis
market to Team SAAS
•
Team SAAS who will supply a TPM cannabis distillate for use in the
manufacture of cannabis gummies
•
Team SAAS will purchase TPM from Avecho with an additional 50:50
profit split.
May 2022
AVECHO BIOTECHNOLOGY I May 2022
More deals to come
15
15
NEW DOSAGE FORMS
TOPICAL CBD TPM GEL: PHASE II OSTEOARTHRITIS
TRIAL
Avecho has completed a Phase II clinical trial in collaboration
with the Lambert Initiative testing a topical CBD gel in patients
suffering osteoarthritis of the hand.
•
N=15 subjects applied a topical CBD gel to painful
fingers/thumbs each day for 4 weeks
•
Pain scores and measurements of grip strength were
recorded each day
•
Functional measurements were recorded once per week.
May 2022
AVECHO BIOTECHNOLOGY I May 2022
CBD from topical vehicles developed for
commercial TPM® formulations (ie. Voveran
TPM) has 3-5x increase in dermal absorption
17
17
PHASE II: TOPICAL CBD TPM IMPROVES PAIN AND GRIP
STRENGTH
CHANGE OVER TIME
40%
“Average Pain” significantly decreased over
the study period (p<0.001)
•
“Maximum Pain” significantly decreased
over the study period (p<0.001)
•
•
Grip Strength significantly increased over
the study period (p<0.001)
Study results being presented at the
International Cannabinoid Research Society
Symposium in June by the Lambert
Larger Phase II studies
planned with the Lambert
Initiative
May 2022
AVECHO BIOTECHNOLOGY I May 2022
Baseline
Average Change from Baseline (%)
•
Active dosing period (30 days)
30%
Treatment
stops
20%
10%
0%
-10%
-20%
-30%
-40%
Average Pain
Maximum Pain
Grip Strength
18
18
GROWING PORTFOLIO OF DIFFERENTIATED
CANNABINOID PRODUCTS
Partner
(Geography)
Product
Therapeutic
Area
CBD Capsule
Sleep
TBD (ANZ)
CBD Capsule
Further indications
TBD
CBD Capsule
Arthritis
Perland (ROW)
CBD Topical Gel
Osteoarthritis
TBD
CBD Topical Gel
Dermatology
TBD
THC oil
(for use in edibles)
Recreational cannabis
Team SAAS (USA)
CBD Oil
Miscellaneous
Comp. pharmacy
CBD Topical Gel
Miscellaneous
Comp pharmacy
May 2022
AVECHO BIOTECHNOLOGY I May 2022
Preclinical
Phase I
Phase II or
Observation
al Study
Phase III
19
Marketed
19
COMPANY OVERVIEW
COMPANY SNAPSHOT
Holdings by Top 20 Shareholders
Cash
R&D tax credit
$2.44M1
+ $1M
8.0%
56.4%
As of 26th May;
Shares
1,838M
Market cap
$31.2M
Options/Performance Rights
217.3M
35.6%
Top 10
Top 11-20
All others
1 Quarter ending 31 March 2022
May 2022
AVECHO BIOTECHNOLOGY I May 2022
21
21
AVECHO MANAGEMENT & BOARD
Dr Paul Gavin
Chief Executive Officer
Dr Roksan Libinaki
Chief Operating Officer
Melanie Leydin
CFO & Company Secretary
− 20+ yrs Avecho
− Ex- AVE CSO
− Inventor TPM® platform
− 20+ yrs Avecho
− Exec MBA
− Co. Operations and clinical
− 25+yrs accounting; 15+ yrs
Co-Sec
− Inst. of Chartered Accts
− MD Vistra Australia
Dr Greg Collier
Chairman
Dr Ross Murdoch
Non-Executive Director
Matt McNamara
Non-Executive Director
− 20+yrs biotech exec
experience
− ex-CEO Chemgenex (sold
$200M+)
− 150 publications, 33
patents
May 2022
AVECHO BIOTECHNOLOGY I May 2022
− 25+yrs biotech exec
experience
− CEO Extractas
− ex-CEO Avecho (20152019)
− ex-SVP Shire Pharma.
− 30+yrs experience
healthcare
− 20+yr venture capital
− previous CIO Bioscience
Managers
22
22
NEWS 2022
•
MANUFACTURING; complete scale-up of the CBD capsule, CMC dossier, registration batches
•
PHASE III INSOMNIA PROGRAM using oral CBD capsule; complete study design, initiate program for
insomnia indication
•
Further PHASE II OSTEOARTHRITIS trial using topical gel
•
Commercial PARTNERING/LICENSING opportunities; new markets, new territories, new indications
•
New DOSAGE FORMS/NEW CANNABINOIDS
May 2022
AVECHO BIOTECHNOLOGY I May 2022
23
23
QUESTIONS WELCOME
Dr Paul Gavin
Chief Executive Officer
T. +61 3 9002 5000
E. pgavin@avecho.com.au
Melbourne Office
Unit A8, 2A Westall Road
Hallmarc Business Park
Clayton VIC 3168
Australia
T: +61 3 9002 5000
E: info@avecho.com.au
Share your feedback
Discover